OBJECTIVES: The growth in per-member-per-year (PMPY) prescription drug utilization among beneficiaries with private or commercial health insurance coverage has slowed over the last six years, after nearly a decade of steady growth. As the prevalence of obesity and related conditions, more choices in lower cost generic medications, and newer drugs to treat chronic conditions. Particularly for the community, the benefit of using lower cost generics and newer drugs to treat chronic conditions, the rising prevalence of obesity and related conditions, more choices in lower cost generic medications, and newer drugs to treat chronic conditions. Particularly for the community, the benefit of using lower cost generics and newer drugs to treat chronic conditions, the rising prevalence of obesity and related conditions, more choices in lower cost generic medications, and newer drugs to treat chronic conditions.

OBJECTIVES: The growth in per-member-per-year (PMPY) prescription drug utilization among beneficiaries with private or commercial health insurance coverage has slowed over the last six years, after nearly a decade of steady growth. As the prevalence of obesity and related conditions, more choices in lower cost generic medications, and newer drugs to treat chronic conditions. Particularly for the community, the benefit of using lower cost generics and newer drugs to treat chronic conditions, the rising prevalence of obesity and related conditions, more choices in lower cost generic medications, and newer drugs to treat chronic conditions. Particularly for the community, the benefit of using lower cost generics and newer drugs to treat chronic conditions, the rising prevalence of obesity and related conditions, more choices in lower cost generic medications, and newer drugs to treat chronic conditions. Particularly for the community, the benefit of using lower cost generics and newer drugs to treat chronic conditions, the rising prevalence of obesity and related conditions, more choices in lower cost generic medications, and newer drugs to treat chronic conditions.